Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,564.80INR
3:57pm IST
Change (% chg)

Rs13.95 (+0.55%)
Prev Close
Rs2,550.85
Open
Rs2,550.00
Day's High
Rs2,577.25
Day's Low
Rs2,518.00
Volume
568,148
Avg. Vol
889,747
52-wk High
Rs2,964.00
52-wk Low
Rs1,872.95

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.20
Market Cap(Mil.): Rs423,157.41
Shares Outstanding(Mil.): 165.89
Dividend: 20.00
Yield (%): 0.78

Financials

  REDY.NS Industry Sector
P/E (TTM): 21.73 32.81 37.60
EPS (TTM): 117.41 -- --
ROI: 11.83 12.52 12.15
ROE: 14.67 13.83 17.02

BUZZ-India's Dr.Reddy's gains most in nearly 13 weeks after U.S FDA report

** Shares of Indian drugmaker Dr.Reddy's Laboratories Ltd climbs as much as 4.9 pct to 2,689.65 rupees, in their biggest intraday pct gain since Nov. 11

18 Feb 2019

Sensex, Nifty extend declines, post two percent weekly fall

Indian shares recovered some of their early losses in late trade on Friday, but subdued global indicators and muted domestic earnings led to the markets ending in the red again.

15 Feb 2019

BUZZ-India's Dr.Reddy's posts sharpest intraday loss in over 17 yrs

** Shares of Indian drugmaker Dr.Reddy's Laboratories Ltd plunge as much as 29.78 pct to 1,872.95 rupees, in their biggest intraday pct loss since Oct 15, 2001

15 Feb 2019

BUZZ-India's Dr.Reddy's hits near 23-mth high; chart suggests more upside

** Shares of Dr.Reddy's Laboratories Ltd gain as much as 3.11 pct to 2,878 rupees, highest since March 7, 2017

04 Feb 2019

Dr. Reddy's third-quarter profit surges on strong growth in emerging markets

Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, handily beating market expectations, helped by strong growth in emerging markets.

01 Feb 2019

UPDATE 1-Indian drugmaker Dr. Reddy's Q3 profit surges on strong growth in emerging markets

Feb 1 Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, handily beating market expectations, helped by strong growth in emerging markets.

01 Feb 2019

Indian drugmaker Dr. Reddy's Q3 profit rises 65.3 pct, beats estimates

Feb 1 Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, driven by strong growth in emerging markets.

01 Feb 2019

Earnings vs. Estimates